In all four studies, patients who took the drug saw better results after 16 weeks than those given a placebo, the regulator said. Britain approves J&J's oral psoriasis pill Icotyde for ages 12+, backed by four trials showing better 16-week results than placebo. Britain’s MHRA has approved Johnson & Johnson's daily pill, Icotyde, for treating moderate-to-severe plaque psoriasis in individuals aged 12 and older.